RNA interference for cancer treatment relies on the ability to directly kill cancer cells via downregulation of target genes but issues of delivery and efficacy have limited clinical adoption.
Introduction
RNA interference (RNAi) has proved to be a powerful tool to specifically silence gene expression and holds great promise for the treatment of genetic disorders, viral diseases, and cancer.
RNAi is mediated by small interfering RNAs (siRNAs) that direct the sequence-specific degradation of target mRNA. To date, the use of RNAi for cancer treatment has mostly relied on the concept of targeting overexpressed or mutated oncogenes to directly kill the cells and while in vitro results have been promising, in vivo experiments have been less impressive. This is in part due to a major impediment to the clinical use of RNAi therapy, namely the need to deliver these macromolecules to the desired cells, tissues or organs in order to elicit gene silencing. Furthermore, to work effectively RNAi therapy needs to be delivered to each and every cancer cell in order to elicit direct and specific killing. Several studies have demonstrated some in vivo efficacy in the delivery of siRNAs using various strategies such as complexing siRNAs with cationic lipids, nanoparticles, polyethyleneimine, cyclodextrin, chitosan, and collagen (see (1) for a review).
One way to overcome these barriers is to harness the immune response to augment RNAi treatment. Some studies have concentrated on manipulating the immune system ex vivo by using RNAi to silence immune response regulatory factors (2, 3) , while others have investigated the role of specific siRNA sequences that are able to induce innate immune responses and upregulate cytokines such as the interferons (4) (5) (6) (7) (8) (9) . However, to the best of our knowledge no one has investigated the use of RNAi to trigger specific adaptive immune responses against the RNAi target. This is partially due to the fact that most previous pre-clinical studies on anti-cancer agents, including RNAi, have used human cancer cells in immune-deficient small animal models such as
Rag
-/-or NOD-SCID mice. While this approach allows direct measurement of the RNAi effect, the role of the adaptive immune system cannot be assessed. The adaptive immune system constantly monitors the internal protein content of cells via the MHC/proteosome system allowing the 4 detection of non-self proteins. It has previously been observed that certain viral antigens appear to be more rapidly presented to the immune system than normal proteins (10) (11) (12) and it has been proposed that this is due to the virus production of defective ribosomal products, incomplete proteins that are misfolded or malformed such that they are shunted to the proteosome for destruction. This is known as the defective ribosome products, (DRiP), hypothesis (13) and the immunoribosome model (13, 14) . Given that RNA interference could potentially result in the generation of defective mRNAs we wondered if a similar mechanism of immune presentation of a target gene was possible.
To address this issue we investigated RNAi therapy using two different antigen systems, the E7 oncoprotein from the human papillomavirus (HPV), the causative agent of cervical cancer, and the classic antigen, ovalbumin. In this study we show that shRNA treatment was able to generate a target-specific immune response capable of protecting mice from challenge with untreated tumour cells and investigate the mechanism by which this occurs.
Results
ShRNA treatment results in truncated mRNA. We hypothesised that RNAi is able to act in the same manner as that proposed for viruses and produce defective ribosome products or DRiPs (13, 14) . We firstly established if truncated mRNA products were generated in cells treated with
shRNAs. As a model system of cancer we targeted the E6/E7 oncogenes from the type 16 human papillomavirus and used TC-1 cells, created by transforming murine lung fibroblasts with E6, E7
and ras (15) . E6 and E7 are expressed from the same mRNA in a biscistronic fashion. Several shRNAs targeting the E6/E7 mRNA were cloned in the vector pLL, which expressed shRNAs from the U6 promotor as well as GFP from the CMV promoter ( Figure 1A ). TC-1 cells were transduced with a low dose of shRNA-bearing lentivirus and FACS-sorted based on GFP expression to achieve 100% transfection of the target cells. We have previously shown that high doses of E6E7 shRNA (12 copies/genome) results in cell death while lower doses (4-5 copies/genome) results in slower 5 cell growth and come cells entering senescence (16) . After four days transfected cells were tested for the presence of E6/E7 mRNA using RT-PCR and a series of primers designed to detect fulllength or various truncated versions of mRNA. Treatment with both E6-1 and E7-1 shRNA resulted in the loss of full-length mRNA ( Figure 1B , R1 fragment) and E7 protein (Fig 1C) . However, a PCR fragment corresponding to the 5' end of the mRNA was still found even in the presence of shRNA ( Figure 1B, R3) utilised another target, ovalbumin (OVA). As before shRNAs were generated to target sites along the length of the OVA gene and OVA-expressing thymoma cells (EG7) were transduced with lentiviruses expressing shRNA-OVA1, -OVA2 or -OVA3 ( Figure 2A ). All three OVA shRNAs were able to reduce the level of full-length OVA protein by 40-60% ( Figure 2B ). To detect the presence of truncated OVA protein shRNA-treated cells were treated with the protease inhibitor MG132, to limit protein degradation, and western blots were performed using antibodies reactive to the extreme N-terminus of ovalbumin. We observed the appearance of a 15kDa protein in cells treated with the OVA2 shRNA, but not in untreated, OVA1-or OVA3-treated cells ( Figure 2C ).
The predicted size of a protein generated by mRNA cleaved by OVA2 shRNA is 14.7kDa. The predicted truncated product generated by OVA3 shRNA treatment was not observed due to cross reacting proteins on the blot. Thus it appears that truncated proteins can be generated in vivo by the protein (17, 18) located between the E6-1 and E7-1 shRNA sites ( Figure 1A , *). After 10 days mice were challenged in the opposite flank with untreated TC-1 cells and tumours allowed to grow until day 20. It can be seen that in all treatments except E7-1, the weights of the primary and 7 challenge tumours were no different to untreated controls ( Figure 3A ). However, in mice treated with tumours bearing the E7-1 shRNA, both the primary and challenge tumours were absent in all mice expect one ( Figure 3A ). Such a result cannot be explained as a direct shRNA effect as challenge tumours were not treated with shRNA. Furthermore, both E6-1 and E7-1 are equally effective at knocking down E7 protein levels ( Figure 1C ) and have similar potency at directly reducing TC-1 cell growth and colony forming ability (Supplementary Figure 1) .
In order to prove an adaptive immune response was required for this effect we repeated the same experiment above using RAG -/-mice, which lack B-, T-, and NKT-cells and thus are unable to mount an adaptive immune response. We now observed no significant differences in either primary Figure 2) . Furthermore, we did not observe non-specific toxicity in HPV18+ve
HeLa cells treated with our HPV16-specific shRNAs (Supplementary Figure 3B) . Finally, to prove the response was target antigen-specific we repeated the experiment once more, immunising 8 C57BL/6 mice with TC-1 cells treated with shRNA, but challenging with another E7-expressing H-2 b cell line, C2. Once again, only in mice immunised with E7-1 was there a loss of tumour formation, thus indicating tumour clearance was specific to our shRNA target, E7 ( Figure 3C ).
It could be argued that we were observing an E7-specific effect in which silencing the E7 gene prevented some key immunomodulatory process. Therefore, to prove the generality of our observation we tested if RNAi-enhanced immunity would work using OVA as the target antigen.
The experiments were repeated as above, but immunizing mice firstly with OVA-1, -2 or -3
shRNA-transduced EG7 cells and subsequently challenging with untreated EG7 cells. We observed that only mice inoculated with OVA3-transduced cells, that is the shRNA downstream of the major CTL epitope, SIINFEKL, had significantly reduced tumour formation following challenge ( Figure   3D ). These data further suggest clearance is dependent on the shRNA target and is not specific to E7 as a target antigen. Also, OVA3-shRNA treatment had no affect on the cell viability, thus eliminating non-specific toxicity as the reason for tumour clearance (Supplementary Figure 3A) .
ShRNA-treated tumours induce target specific CTLs in mice.
Finally in order to address the mechanism by which RNAi-mediated immune enhancement was occurring we directly measured the activity of E7-specific CTLs in mice immunised with our shRNAs. Twenty days after inoculation with shRNA-treated TC-1 tumour, ex vivo splenocytes were tested in an IFNγ ELISPOT assay in the presence of the E7-CTL epitope peptide. Significantly more IFNγ-secreting cells were recorded in the spleens of mice inoculated with E7-1 treated tumour than E6-1 treated tumour ( Figure 4A ), despite the fact that both reduced total protein levels by the same amount ( Figure 1C ).
Moreover, these cells were capable of specifically killing syngeneic target cells pulsed with E7-CTL epitope peptide in a MHC (H-2 b )-restricted fashion, after restimulation ( Figure 4B ).
Additionally, restimulated splenocytes from mice inoculated with E7-1-treated tumour were significantly more effective than splenocytes from E6-1-inncoulated mice in killing C2 target cells which endogenously express whole E7 oncoprotein and present the E7 CTL epitope (22) ( Figure   4C ).
Discussion.
We Although each shRNAs silenced expression equally well they gave remarkably different outcomes in vivo. The shRNA targeted downstream of the E7 CTL epitope shRNA had the ability to induce E7-specific immune responses against the tumor such that both primary, shRNA-treated, and secondary, untreated tumors were eliminated. However the upstream shRNA had no effect in vivo on either primary or secondary tumors. There are a number of possible explanations for this effect that may be related to loss of E6 and E7 itself. For example, Xue et al recently showed that restoration of p53 in liver carcinoma cells resulted in cellular senescence followed by tumor clearance that was mediated by the innate immune system (19) . This clearance required macrophages, neutrophils or NK cells. We have previously shown that the loss of E6, via shRNA treatment, causes increased p53 levels and induction of cellular senescence, depending on the dose of LV used (16) . However, we did not observe immune clearance in Rag -/-mice, which lack B-, T-, Cells, lentiviral-shRNA production, cell transduction, and flow cytometry sorting. Lentiviral production and titration were as previously described (16) . TC1 and 293T cells were maintained in DMEM supplemented with 10% heat-inactivated foetal calf serum, 100 units/ml penicillin G, 100ug/ml streptomycin sulphate and 0.29mg/ml of L-Glutamine (Gibco-Invitrogen). TC-1(H-2 b ), C2 and EG7 cells have been previously described (15, 22, 32) . EL4.A2 and P815 cells are susceptible to specific CTL lysis restricted through H-2 b and H-2 d respectively. C2, EG7, and EL4 cells were maintained in Click's medium (equal volume of Eagle's Ham Amino Acids (Sigma) and RPMI Medium 1640 (Gibco); 10% heat-inactivated foetal calf serum; 100 U/ml penicillin, 100ug/ml streptomycin, 0.292 mg/ml L-glutamine; and 0.0035% 2-mercaptoethanol (Sigma)). For transduction, the cells were plated in 6-well plates (1x10 5 cells /well) or in T75 flasks (3x 10 5 /flask) and were cultured overnight. LV-shRNAs diluted (in cultural medium containing polybrene 8µg/ml) or not diluted were added to the cells containing 0.5ml (6-well plate) or 5ml (flask) polybrene-medium for incubation for 1 hour at 37 o C. After this, 1ml or 5ml of fresh polybrenemedium was added to the cells and incubation continued for 48 hours. Polybrene-medium was then replaced with fresh culture medium and the cells were further cultured for assays. TC1 cells were 13 harvested by trypsin and washed 2 times with PBS before being resuspended in 0.5ml 1% paraformaldehyde/PBS for flow cytometry analysis using FACS Calibur. Transduced C2 or EG7 cells were harvested by centrifugation and washed in PBS followed by cell sorting using flow cytometry MoFlo.
RT-PCR for mRNA and short-form mRNA detection. Transduced and sorted TC1 cells were cultured for 2 to 4 days and harvested for total RNA extraction using TRIzol® reagent (Invitrogen)
following the manufacturers' instructions. However, for truncated mRNA detection, the isopropanol Murine IFN-© ELISPOT assay. Epitope-specific gamma interferon (IFN-γ) secreting spleen cells were enumerated ex vivo by an enzyme-linked immunospot (ELISPOT) assay with or without E7 CD8 + T-cell epitope peptide, essentially as described (35) . IFN-γ spots were counted using an AID ELISPOT reader system. Results were calculated as IFN-γ positive cells/10 6 spleen cells.
51 Cr-release CTL assay. CTL assays were conducted as previously described (35) . In summary, splenocytes were restimulated in vitro for 6 days as described (35) .
Data analysis Data were collected and were appropriate statistical comparison was made using the student's unpaired t-test. 
